Ultrasound contrast agent developer Acusphere of Cambridge, MA, has begun phase II clinical trials of its third-generation agent for assessing myocardial perfusion in patients with coronary artery disease (CAD). The company’s phase II trial will
Ultrasound contrast agent developer Acusphere of Cambridge, MA, has begun phase II clinical trials of its third-generation agent for assessing myocardial perfusion in patients with coronary artery disease (CAD). The companys phase II trial will evaluate the best imaging conditions for the assessment of myocardial perfusion in patients with CAD after a single dose of AI-700. Acusphere hopes that AI-700 could offer clinicians a low-cost alternative to nuclear medicine perfusion scans.
First-generation agents last for about a minute when illuminating the endocardium within the ventricles of the heart. Second-generation technology provides four or five minutes of continuous imaging in this application. Ultrasound contrast developers such as Acusphere hope that third-generation agents will extend imaging time to 20 to 30 minutes, or about the time of a cardiac ultrasound examination (SCAN 6/23/99).
Studies have suggested that AI-700 could be used in a continuous mode, allowing clinicians to overcome some of the shortcomings of other agents, which have short persistence times because their contrast-enhancing microbubbles break up under ultrasound beams, according to the company (SCAN 4/14/99). Acusphere believes that the AI-700 microbubbles may have longer persistence times because they are made from synthetic polymers.
European Society of Breast Imaging Issues Updated Breast Cancer Screening Recommendations
April 24th 2024One of the recommendations from the European Society of Breast Imaging (EUSOBI) is annual breast MRI exams starting at 25 years of age for women deemed to be at high risk for breast cancer.
Study Reveals Benefits of Photon-Counting CT for Assessing Acute Pulmonary Embolism
April 23rd 2024In comparison to energy-integrating detector CT for the workup of suspected acute pulmonary embolism, the use of photon-counting detector CT reduced radiation dosing by 48 percent, according to newly published research.
Could a Newly FDA-Cleared C-Arm Device Bolster Efficiency for Interventional Radiologists?
April 22nd 2024In addition to advanced imaging quality and dose efficiency, the Philips Zenition 30 mobile C-arm device emphasizes personalized user profiles and automated customization to help reduce procedure time.